Sanaei Sara, Hashemi Mohammad, Eskandari Ebrahim, Hashemi Seyed Mehdi, Bahari Gholamreza
Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran. Email:
Asian Pac J Cancer Prev. 2017 May 1;18(5):1301-1305. doi: 10.22034/APJCP.2017.18.5.1301.
Single nucleotide polymorphisms (SNPs) in the let-7 miRNA binding site within the 3’ untranslated region (3’UTR) of KRAS appear related to the risk of cancer. The present case-control study was conducted with 244 BC patients and 204 healthy women to examine whether KRAS polymorphisms (rs61764370 T/G and rs712 G/T) are associated with breast cancer (BC) risk in an Iranian population. The polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method was used for genotyping of KRAS SNPs. Our results showed that the rs61764370 TG genotype (OR= 3.73; 95% CI =1.38-10.08; P=0.007) as well as the G allele OR= 3.56; 95% CI =1.33-9.53; P=0.008, respectively) increased the risk of BC. However, the KRAS rs712 TT vs GG+GT genotype in a recessive model was associated with a reduced risk of BC (OR= 0.56; 95% CI =0.38-0.84; P=0.006). In addition, the rs712 T allele decreased the risk of BC compared with the G allele (OR=0.75, 95%CI=0.58-0.97, P=0.031). However, we found no relationship among KRAS SNPs and clinicopathological characteristics of BC patients (P>0.05). Taken together, the present study provided evidence of relationships between KRAS polymorphisms and BC risk in a southeast Iranian population. Additional studies using larger sample sizes and diverse ethnicities are now warranted.
KRAS基因3'非翻译区(3'UTR)中let-7 miRNA结合位点的单核苷酸多态性(SNP)似乎与癌症风险相关。本病例对照研究纳入了244例乳腺癌患者和204名健康女性,以检验KRAS基因多态性(rs61764370 T/G和rs712 G/T)是否与伊朗人群的乳腺癌(BC)风险相关。采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法对KRAS基因SNP进行基因分型。我们的结果显示,rs61764370的TG基因型(OR = 3.73;95%CI = 1.38 - 10.08;P = 0.007)以及G等位基因(OR = 3.56;95%CI = 1.33 - 9.53;P = 0.008)分别增加了BC风险。然而,在隐性模型中,KRAS rs712的TT基因型与GG + GT基因型相比,BC风险降低(OR = 0.56;95%CI = 0.38 - 0.84;P = 0.006)。此外,与G等位基因相比,rs712的T等位基因降低了BC风险(OR = 0.75,95%CI = 0.58 - 0.97,P = 0.031)。然而,我们发现KRAS基因SNP与BC患者的临床病理特征之间没有关系(P>0.05)。综上所述,本研究提供了伊朗东南部人群中KRAS基因多态性与BC风险之间关系的证据。现在需要使用更大样本量和不同种族进行更多研究。